309 related articles for article (PubMed ID: 21495876)
1. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?
Klasse PJ; Sanders RW; Cerutti A; Moore JP
AIDS Res Hum Retroviruses; 2012 Jan; 28(1):1-15. PubMed ID: 21495876
[TBL] [Abstract][Full Text] [Related]
2. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
3. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
5. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
6. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.
Monini P; Cafaro A; Srivastava IK; Moretti S; Sharma VA; Andreini C; Chiozzini C; Ferrantelli F; Cossut MR; Tripiciano A; Nappi F; Longo O; Bellino S; Picconi O; Fanales-Belasio E; Borsetti A; Toschi E; Schiavoni I; Bacigalupo I; Kan E; Sernicola L; Maggiorella MT; Montin K; Porcu M; Leone P; Leone P; Collacchi B; Palladino C; Ridolfi B; Falchi M; Macchia I; Ulmer JB; Buttò S; Sgadari C; Magnani M; Federico MP; Titti F; Banci L; Dallocchio F; Rappuoli R; Ensoli F; Barnett SW; Garaci E; Ensoli B
PLoS One; 2012; 7(11):e48781. PubMed ID: 23152803
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.
Yang L; Song Y; Li X; Huang X; Liu J; Ding H; Zhu P; Zhou P
J Virol; 2012 Jul; 86(14):7662-76. PubMed ID: 22553333
[TBL] [Abstract][Full Text] [Related]
10. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
11. BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.
Dosenovic P; Soldemo M; Scholz JL; O'Dell S; Grasset EK; Pelletier N; Karlsson MC; Mascola JR; Wyatt RT; Cancro MP; Karlsson Hedestam GB
J Immunol; 2012 Jun; 188(12):6018-26. PubMed ID: 22561155
[TBL] [Abstract][Full Text] [Related]
12. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
[TBL] [Abstract][Full Text] [Related]
13. A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing.
Datta R; Roy Chowdhury R; Manjunath K; Hanna LE; Varadarajan R
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29584-29594. PubMed ID: 33168755
[TBL] [Abstract][Full Text] [Related]
14. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
15. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.
Ringe RP; Pugach P; Cottrell CA; LaBranche CC; Seabright GE; Ketas TJ; Ozorowski G; Kumar S; Schorcht A; van Gils MJ; Crispin M; Montefiori DC; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487280
[TBL] [Abstract][Full Text] [Related]
16. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
17. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
[TBL] [Abstract][Full Text] [Related]
18. Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
Bresk CA; Hofer T; Wilmschen S; Krismer M; Beierfuß A; Effantin G; Weissenhorn W; Hogan MJ; Jordan APO; Gelman RS; Montefiori DC; Liao HX; Schmitz JE; Haynes BF; von Laer D; Kimpel J
Viruses; 2019 Feb; 11(2):. PubMed ID: 30769947
[TBL] [Abstract][Full Text] [Related]
19. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
[TBL] [Abstract][Full Text] [Related]
20. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
